Download - AWMF

Weitere Magazine

Empfehlungen

Info

Leitlinien für Diagnostik und Therapie in der Neurologie Hilton-Jones D. When the patient fails to respond to treatment: myasthenia gravis. Pract Neurol 2007; 7: 405–411 Hoch W, McConville J, Helms S et al. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetyle choline receptor antibodies. Nature Med 2001; 7: 365–368 Hoeltzenbein M, Weber-Schoendorfer C, Borisch C et al. Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine. Reprod Toxicol 2012 May 16. [Epub ahead of print] Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol 2007; 14: 38–43 Hohlfeld R, Goebels N, Engel AG. Cellular mechanisms in inflammatory myopathies. Baillieres Clin Neurol 1993; 2: 617–635 Hohlfeld R, Michels M, Heininger K et al. Azathioprine toxicity during long-term immunosuppression of generalized myasthenia gravis. Neurology 1988; 38: 258–261 Hohlfeld R, Toyka KV, Besinger UA et al. Myasthenia gravis: reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985; 17: 238–242 Howard JF. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Neurology 1998; 51: S30-S36 Illa I, Diaz-Manera J, Rojas-Garcia R et al. Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients. J Neuroimmunol 2008 15; 201: 90–94 Imbach P, Barandim S, D'Apuzzo V et al. High dose intravenous gammaglobulin for idiopathic thombocytopenia purpura in childhood. Lancet 1981; 1: 1228–1231 Jackson CE, Gronseth G, Rosenfeld J et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009; 39: 137–143 Jani-Aesadi A, Lisak OP. Myasthenic crisis: Guidelines for prevention and treatment. J Neurol Sci 2007; 261: 127– 133 Jaretzki A, Barohn RJ, Ernstoff RM et al. Myasthenia gravis – recommendations for clinical research standards. Neurology 2000; 55: 16–23 Jaretzki A, Penn AS, YOunger DS et al. Maximal thymectomy for myasthenia gravis. Results. J Thorac Cardiovasc Surg 1988; 95: 747–757 Jha S, Xu KP, Maruta T et al. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J Neuroimmunol 2006; 175: 107–117 Kearsey C, Fernando P, D'Costa D et al. The use of the ice pack test in myasthenia gravis. JRSM short reports 2010; 1: 14 Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011; 2: CD003279 Konishi T, Yoshiyama Y, Takamori M et al., Japanese FKMGSG. Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus). J Neurol Neurosurg Psychiatry 2005; 76: 448–450 Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 2009; 256: 1314–1320 Lacomis D. Myasthenic crisis. Neurocritl Care 2005; 3: 189–194 Lambert EH, Eaton LM, Rooke ED. Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 1956; 187: 612–613 Lambert EH, Elmqvist D. Quantal components of end-plate potentials in myasthenic syndrome. Ann NY Acad Sci 1971; 183: 183–199 Laurolia F, Ranelletti F, Maggianno N et al. Thymus changes in anti-MuSK-positive myasthenia gravis. Neurology 2005; 64: 536–538 Lebrun C, Bourg V, Tieulie N et al. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009; 16: 246–250 Leite MI, Strobel P, Jones M et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005; 57: 444–497 Leite MI, Waters P, Vincent A. Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity 2010; 43: 371– 379 Lemma GL, Lee JW, Aisner SC et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 2011; 29: 2060–2065 Lin PT, Martin BA, Weinacker AB et al. High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies. Muscle Nerve 2006; 33: 433–435 Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolon pulse: a double blind study. Acta Neurol Scand 1998; 97: 370–373 Loehrer PJ, Kim K, Aisner SC et al. Cisiplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymomy – final results of an intergroup trial. J Clin Oncol 1994; 12: 1164–1168 Luchanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol 2008; 21: 8–15 Luther C, Poeschel S, Varga M et al. Decreased frequency of intrathymic regulatory T cells in patients with myasthenia-associated thymoma. J Neuroimmunol 2005; 164: 124–128 Maddison P, McConville J, Farrugia ME et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011; 82: 671–673 Mantegazza R, Antozzi C, Peluchetti D et al. Azathioprine as a single drug or in combination with steroids in the 26
Leitlinien für Diagnostik und Therapie in der Neurologie treatment of myasthenia gravis. J Neurology 1988; 235: 449–453 Martignano S, Fanin M, Albertini E et al. Muscle histopathology in myasthenia gravis with antibodies against MuSK and AChR. Neuropathol Appl Neurobiol 2009; 35: 103–110 Masaoka A, Monden Y, Nakahara K et al. Follow-up-study of thymomas with special reference to their clinical stages. Cancer 1981; 48: 2485–2492 McEvoy KM, Windebank AJ, Daube JR et al. 3,4-diaminopyridine in the treatment of Lambert-Eaton Myasthenic syndrome. N Engl J Med 1989; 321: 1567–1571 Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev 2011; 2: CD006986 Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8: 475–490 Mertens HG, Balzerei F, Leipert M. Treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol 1969; 2: 321-326 Meyer DM, Herbert MA, Sobhani NC et al. Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches. Ann Thorac Surg 2009; 87: 385–391 Michels M, Hohlfeld R, Hartung HP et al. Myasthenia gravis – discontinuation of long-term azathioprine. Ann Neurol 1988; 24: 798 Miescher A, Daldrup J, Forssman WG et al. Sideroblastic anemia and inclusion bodies – microscopic and ultrastructural studies. Schweiz Med Wschr 1970; 100: 1981–1982 Miescher PA. Systemic lupus erythematosus. Verh Dtsch Ges Inn Med 1977; 83: 1807–1813 Miescher PA. Immune complexes and systemic lupus erythematosus. Folia Allergol 1970; 17: 428 Miescher PA, Lambert PH. Immunosuppressive therapy of lupus erythematosus. Therap Umsch 1971; 28: 579– 585 Minami N, Fujiki N, Doi S et al. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J Neurol Sci 2011; 300: 59–62 Motomura M, Johnston I, Lang B et al. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995; 58: 85–87 Müller-Hermelink HK, Marx A. Towards a histogenetic classification of thymic epithelial tumours? Histopathology 2000; 36: 466–469 Mueller JS, Herczegfalvi A, Vilchez JJ et al. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain 2007; 130: 1497–506 Murray EL, Kedar S, Vedanarayanan VV. Transmission of maternal muscle-specific tyrosine kinase (MuSK) to offspring: report of two cases. J Clin Neuromusc Dis 2010; 12: 76–79 Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71: 394–399 Nagaishi A, Yukitake M, Kuroda Y. Long-term treatment of steroid-dependent myasthenia gravis patients with lowdose tacrolimus. Intern Med 2008; 47: 731–736 Nagane Y, Utsugisawa K, Obara D et al. Efficacy of low-dose FK506 in the treatment of myasthenia gravis – a randomized pilot study. Eur Neurol 2005; 53: 146–150 Nelson RP jr, Pascuzzi RM, Kessler K et al. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review. J Clin Neuromusc Dis 2009; 10: 170–177 Newsom-Davis J, Murray NMF. Plasma-exchange and immunosuppressive drug-treatment in the Lambert-Eaton myasthenic syndrome. Neurology 1984; 34: 480–485 Newsom-Davis J, Vincent A, Wilson SG et al. Plasmapheresis for myasthenia gravis. N Engl J Med 1978; 298: 456–457 Niakan E, Harati Y, Rolak LA. Immunosuppressive drug-therapy in myasthenia gravis. Arch Neurol 1986; 43: 155– 156 Niks EH, Kuks JBM, Wokke JHJ et al. Pre- and postsynaptic neuromuscular junction abnormalities in MuSK myasthenia. Muscle Nerve 2010; 42: 283–288 Novellini L, Longoni M, Spinelli L et al. Extended thymectomy, without sternotomy, performed by cervicotomy and thoracoscopic technique in the treatment of myasthenia gravis. Intern Surg 1994; 79: 378–381 O'Carroll P, Bertorini TE, Jacob G et al. Transient neonatal myasthenia gravis in a baby born to a mother with newonset anti-MuSK-mediated myasthenia gravis. J Clin Neuromusc Dis 2009; 11: 69–71 O'Donovan P, Perrett CM, Zhang XH et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871–1874 Oh SJ, Claussen GG, Hatanaka Y et al. 3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 2009; 40: 795–800 O'Neill JH, Murray NMF, Newsomdavis J. The Lambert-Eaton myasthenic syndrome – a review of 50 cases. Brain 1988; 111: 577–596 Pakzad Z, Aziz T, Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia and Canada. Neurology 2011; 76: 1526–1528 Palace J, Newsom-Davis J, Lecky B, Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998; 50: 1778–1783 Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis – report of 116 patients. Ann Neurol 1984; 15: 291–298 27
Seite 1 und 2: Leitlinien für Diagnostik und Ther
Seite 25: Leitlinien für Diagnostik und Ther

Download - AWMF

Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.

Template löschen?

Als Template speichern?